SequelSEC

Scilex Holding Co SCLX

Biological Products, (No Diagnostic Substances) · CIK 0001820190 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$7.64M
Fiscal year ended 2026-06-30
Operating income
-$29.42M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Scilex Holding Co (SCLX) reported revenue of $7.64M and net income of -$114.99M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Scilex Holding Co’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Scilex Holding Co income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$7.64M$8.61M$4.79M$10.56M$9.90M$5.00M$14.90M$14.44M$16.37M$10.88M
Cost of revenueUnavailableUnavailable$2.61M$3.33MUnavailableUnavailable$4.69M$3.77M$4.39M$3.84M
Gross profitUnavailableUnavailable$2.18M$7.23MUnavailableUnavailable$10.21M$10.67M$11.98M$7.04M
Operating income-$29.42M-$32.17M-$111.09M-$186.51M-$20.51M-$27.90M-$28.38M-$19.92M-$15.62M-$19.48M
Net income-$114.99M-$45.65M-$46.10M-$257.82M-$44.05M-$26.08M-$6.46M-$4.39M-$37.58M-$24.38M
Research & development$3.34M$3.21M$8.17M$3.90M$6.19M$2.46M$2.18M$2.35M$2.00M$3.11M
Weighted-average diluted sharesshares 6.89Mshares 6.89MUnavailableUnavailableshares 11.60Mshares 11.56MUnavailableUnavailableUnavailableUnavailable
Pretax income-$114.98M-$45.65M-$46.10M-$257.82M-$44.03M-$26.08M-$6.46M-$4.39M-$37.58M-$24.38M
Income tax expense$7.00KUnavailable$6.00K$1.00K$19.00KUnavailable-$1.00K$0$0$0
Diluted EPS$-16.65$-6.28Unavailable$-22.17$-7.42$-2.26Unavailable$-0.58$-7.67$-8.33
Selling, general & administrative$27.96M$31.03M$30.16M$188.82M$19.84M$28.06M$35.41M$29.73M$24.60M$29.28M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Scilex Holding Co balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$566.00K$3.35M$4.96M$878.00K$4.10M$5.80M$3.27M$77.00K$6.89M$1.82M
Total assets$253.56M$293.64M$364.98M$275.88M$83.76M$78.98M$92.95M$100.43M$104.54M$91.24M
Current assets$36.24M$41.97M$38.36M$16.49M$33.67M$28.70M$41.55M$39.86M$50.42M$37.74M
Total liabilities$564.05M$547.70M$576.73M$455.60M$332.74M$290.46M$285.59M$311.75M$319.24M$281.03M
Current liabilities$512.24M$501.75M$483.65M$358.95M$305.93M$275.74M$259.64M$281.54M$255.45M$252.73M
Total equity incl. NCI-$310.49M-$254.07M-$211.75M-$179.72M-$248.99M-$211.48M-$192.64M-$211.32M-$214.69M-$189.79M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$4.17M$4.53M$4.79M$1.08M$2.52M$3.02M$2.44M$2.40M$3.07M$3.49M
Accounts receivable$6.44M$10.65M$15.24M$11.94M$16.77M$10.62M$26.44M$31.58M$38.00M$29.72M
Goodwill$13.48M$13.48M$13.48M$13.48M$13.48M$13.48M$13.48M$13.48M$13.48M$13.48M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$121.05M$101.58M$86.27M$67.36M$59.16M$57.26M$52.62M$43.40M$41.79M$42.22M

Cash flow

Scilex Holding Co cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$6.74M-$1.11M-$17.47M$8.23M$7.05M$6.01M$2.53M$5.11M$2.31M$9.39M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0UnavailableUnavailable
Investing cash flow$8.45M-$9.16M$4.78M-$152.00K-$153.00K-$395.00K-$195.00K-$2.18M-$150.00K-$150.00K
Financing cash flow-$4.48M$9.14M$17.52M-$11.30M-$8.60M-$3.08M-$7.18M-$4.48M$4.73M-$11.20M
Net change in cash-$2.78M-$1.60M$4.08M-$3.22M-$1.70M$2.53M-$4.84M-$1.55M$6.89M-$1.96M
Stock-based compensation$3.60M$3.63M$5.64M$3.26M$3.28M$3.31M$4.80M$3.71M$3.61M$3.56M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$2.84M$2.87M$1.59M$1.02M$1.01M$1.00M$1.00M$1.00M$1.01M$1.03M

Derived

Scilex Holding Co derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$2.53MUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailable45.5%68.5%UnavailableUnavailable68.5%73.9%73.2%64.7%
Operating margin-385.0%-373.5%-2317.8%-1766.2%-207.2%-557.5%-190.5%-138.0%-95.4%-179.0%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable17.0%UnavailableUnavailableUnavailable
SBC / revenue47.0%42.1%117.7%30.8%Unavailable66.2%32.2%25.7%UnavailableUnavailable
Current ratio0.07x0.08x0.08x0.05x0.11x0.10x0.16x0.14x0.20x0.15x
Revenue YoY growth-22.8%72.1%-67.8%-26.8%-39.5%-54.0%10.7%42.7%30.1%2.9%
Net margin-1504.7%Unavailable-961.9%-2441.5%-445.1%Unavailable-43.4%-30.4%UnavailableUnavailable
R&D / revenue43.7%37.3%170.4%36.9%62.5%49.1%14.6%16.3%12.2%28.6%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable0.0%UnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SCLX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-04-10View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Reconciliation checks needing review

5 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-06-30

Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue could not be reconciled with the rest of this filer’s statement.

balance equationreview2022-09-30

Difference 217391990 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.